Viking Therapeutics plans Phase 3 clinical trial for oral VK2735 formulation
VKTX Viking Therapeutics Inc
$28.51 +2.81%
View chart & analysis → - 1Viking Therapeutics plans to start the Phase 3 clinical trial for the oral formulation of VK2735 in the fourth quarter.
- 2In the Phase 2 trial, patients taking the medication recorded a 12.2% reduction in body weight over 13 weeks.
- 3The discontinuation rate of patients receiving VK2735 due to side effects is 20%.
So what's the key point?
Viking Therapeutics is scheduled to begin final testing of its oral medication at the end of this year. Previous testing showed results where patient body weight decreased by 12.2 percent.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.